We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.07B
AUM Growth
-$246M
Cap. Flow
-$27.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
57.38%
Holding
61
New
4
Increased
17
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$56M
2
RVMD icon
Revolution Medicines
RVMD
+$38.7M
3
CTMX icon
CytomX Therapeutics
CTMX
+$22M
4
BDTX icon
Black Diamond Therapeutics
BDTX
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$11.4M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$59.5M
2
RCUS icon
Arcus Biosciences
RCUS
+$44M
3
CYTK icon
Cytokinetics
CYTK
+$41.7M
4
BPMC
Blueprint Medicines
BPMC
+$14.7M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
26
X4 Pharmaceuticals
XFOR
$379M
$11.7M 1.09%
39,058
+992
+3% +$281K
EPIX
27
DELISTED
ESSA Pharma
EPIX
$9.68M 0.9%
2,420,565
-220,000
-8% -$1.11M
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$9.49M 0.88%
191,266
+56,879
+42% +$3.41M
BDTX icon
29
Black Diamond Therapeutics
BDTX
$96.3M
$9.45M 0.88%
+378,788
New +$11.5M
RNAC icon
30
Cartesian Therapeutics
RNAC
$224M
$8.7M 0.81%
120,316
+10,847
+10% +$1.05M
LITS
31
Lite Strategy Inc
LITS
$30.9M
$8.12M 0.76%
252,314
-15,000
-6% -$600K
KZR
32
DELISTED
Kezar Life Sciences
KZR
$6.82M 0.64%
156,437
+144,766
+1,240% +$5.89M
CTIC
33
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.38M 0.59%
6,929,690
– –
GLMD icon
34
Galmed Pharmaceuticals
GLMD
$4.98M
$6.34M 0.59%
10,180
– –
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$6M 0.56%
282,862
-168,147
-37% -$3.61M
FWP
36
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.38M 0.5%
925,724
– –
IDYA icon
37
IDEAYA Biosciences
IDYA
$3.45B
$5.29M 0.49%
1,284,829
-151,600
-11% -$1.07M
PRVL
38
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$5.26M 0.49%
431,483
-225,000
-34% -$3.58M
PTGX icon
39
Protagonist Therapeutics
PTGX
$8.65B
$4.89M 0.46%
692,430
+9,800
+1% +$73.4K
STRO icon
40
Sutro Biopharma
STRO
$403M
$4.85M 0.45%
47,548
+13,028
+38% +$1.37M
SPRO icon
41
Spero Therapeutics
SPRO
$69.5M
$4.55M 0.42%
563,393
-282,012
-33% -$2.49M
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$1.09B
$4.55M 0.42%
2,156,740
+529,172
+33% +$2.15M
OVID icon
43
Ovid Therapeutics
OVID
$431M
$3.83M 0.36%
1,286,004
+551,703
+75% +$1.86M
GNCA
44
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.61M 0.34%
2,100,305
– –
PHXM
45
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$3.34M 0.31%
62,500
– –
ARGX icon
46
argenx
ARGX
$53.7B
$3.29M 0.31%
25,000
– –
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.28M 0.31%
1,137,764
– –
GMDA
48
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.02M 0.28%
1,000,000
– –
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.57M 0.24%
176,998
– –
BLRX
50
BioLineRX
BLRX
$11.5M
$2.31M 0.21%
43,326
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2020 Portfolio in Review

As of Q1 2020, BVF Inc held 61 positions worth $1.07B, down 19% from $1.32B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

BVF Inc's Q1 2020 filing shows 4 new, 17 increased, 18 reduced and 4 closed positions. Its largest new stake was Xencor: 1,689,300 shares worth $50.5M. The largest sale was Arqule Inc, an estimated $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

  • BVF Inc's largest Q1 2020 buy was Xencor: 1,689,300 shares worth $50.5M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2020, an estimated $22M increase.
  • BVF Inc's biggest Q1 2020 reduction was Arcus Biosciences, cutting an estimated $44M.
  • BVF Inc fully exited Arqule Inc in Q1 2020, selling an estimated $59.5M.
  • BVF Inc's ten largest holdings make up 57% of its $1.07B portfolio in Q1 2020.
  • BVF Inc opened 4 new positions and closed 4 in Q1 2020.
  • BVF Inc's portfolio value fell 19% quarter-over-quarter to $1.07B.

Based on BVF Inc's 13F filing for Q1 2020, filed 15 May 2020.